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ABSTRACT
Mirtrons are a recently described category of
microRNA (miRNA) relying on splicing rather than
processing by the microprocessor complex to
generate pre-miRNA precursors of the RNA interfer-
ence (RNAi) pathway. Their discovery and subse-
quent verification provides important information
about a distinct class of miRNA and inherent advan-
tages that could be exploited to silence genes
of interest. These include micro-processor-
independent biogenesis, pol-II-dependent tran-
scription, accurate species generation and the
delivery of multiple artificial mirtrons as introns
within a single host transcript. Here we determined
the sequence motifs required for correct processing
of the mmu-miR-1224 mirtron and incorporated
these into artificial mirtrons targeting Parkinson’s
disease-associated LRRK2 and a-synuclein genes.
By incorporating these rules associated with pro-
cessing and splicing, artificial mirtrons could be
designed and made to silence complementary
targets either at the mRNA or protein level. We
further demonstrate with a LRRK2 targeting artificial
mirtron that neuronal-specific silencing can be
directed under the control of the human synapsin
promoter. Finally, multiple mirtrons were
co-delivered within a single host transcript, an
eGFP reporter, to allow simultaneous targeting of
two or more targets in a combinatorial approach.
Thus, the unique characteristics of artificial
mirtrons make this an attractive approach for
future RNAi applications.
INTRODUCTION
The ability to knockdown genes of interest with RNA
interference (RNAi) has revolutionized the way in which
gene function has been studied, while exploitation of the
highly potent and sequence-speciﬁc silencing capabilities
of RNAi holds potential as a therapeutic strategy (1).
Several RNAi effectors have been developed in recent
years. These include, but are not limited to, small
interfering RNAs (siRNAs) (2), small-internally seg-
mented interfering RNAs (sisiRNAs) (3), asymmetric
interfering RNAs (aiRNAs) (4), short hairpin RNAs
(shRNAs) (5), tandem-shRNAs (6) and primary-
microRNA (pri-miRNA) mimics (7). While the effector
used for each application must be carefully considered, it
has been argued by us (8), and others (9), that pri-miRNA
mimics are the safest option where long-term
DNA-induced expression is desirable. Pol-III transcribed
systems such as shRNAs and tandem shRNAs are difﬁcult
to spatially restrict, while high levels of expression can
lead to toxic accumulation of precursors that compete
with endogenous miRNAs for RNAi pathway elements
(10). Both problems are limited with pri-miRNA mimics
as these can be expressed off pol-II promoters. This
approach can restrict expression to only desired cell popu-
lations (11), and the typically lower levels of expression
result in less competition for the endogenous RNAi
pathway (9,10). Further, pri-miRNA mimics can be
co-delivered in pri-miRNA cluster mimics to allow com-
binatorial targeting from the same construct.
Mirtrons are a novel class of miRNA which use a
splicing-dependent mode of biogenesis that is distinct
from the canonical miRNA pathway, which typically
depends on processing of pri-miRNA transcripts by the
Drosha/DGCR8 microprocessor complex (12,13).
Recently we have experimentally validated the biogenesis
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of previously predicted mammalian mirtrons and estab-
lished a mirtron expression system for use in mammalian
systems (14). The discovery of mirtrons has further
improved our understanding of RNAi biology and
added to the complexity of RNAi regulation within the
cells. However, mirtrons also provide a novel way of ex-
ploiting the RNAi pathway for both research and thera-
peutic purposes. As with pri-miRNA mimics and
pri-miRNA cluster mimics, mirtrons can in theory be ex-
pressed from a Pol-II promoter to potentially allow for
spatiotemporal control of expression (15). In addition,
the potential ability to deliver multiple mirtrons as
introns within a host transcript compares with the multi-
plexing properties of the miRNA cluster mimics (7).
However, mirtrons have the additional advantage over
these two strategies in that they bypass Drosha processing
(12,13,16). The dependence on splicing rather than Drosha
processing for pre-miRNA hairpin formation implies that
mirtrons would be less dependent on the canonical
miRNA biogenesis pathway, which previous research
has shown to be capable of saturation (9,10,17). We there-
fore reasoned that exploiting the mirtron pathway could
be an attractive RNAi strategy for future applications.
In this report, we add artiﬁcial mirtrons to the RNAi
arsenal. Speciﬁcally, we describe the characterization and
engineering of the mouse miR-1224 mirtron into artiﬁcial
mirtrons that target Parkinson’s disease (PD)-linked
LRRK2 and a-synuclein transcripts. We further demon-
strate that artiﬁcial mirtrons can initiate RNAi silencing
effects comparable to those of shRNAs and have the ad-
vantages that they can be expressed from within useful
host transcripts and may be paired with pol-II promoters
to direct cell-type-speciﬁc expression and gene silencing.
This work provides a novel gene silencing platform with




Mirtron constructs and splicing-deﬁcient variants were
designed as previously described, with annealed oligo-
nucleotides containing intronic sequences ligated into the
BbsI (NEB, MA, USA) digested pEGFP-Mirt plasmid
(14). The dual mirtron variant containing miR-877 and
miR-1226 was made by overlapping polymerase chain
reaction (PCR) of the 30-portion of eGFP using the pre-
viously reported pEGFP-Mirt-877 plasmid as template
(14) and primers containing miR-1226 overhangs.
Brieﬂy, the 30-fragment of eGFP in this plasmid was
divided into two smaller fragments by PCR, with a
miR-1226 sequence overhang incorporated into the
reverse primer of the ﬁrst PCR and the forward primer
of the second PCR. The resultant PCR products were then
added to a PCR mixture at a molar ratio of 1:1 for
overlapping PCR to create a new eGFP 30-fragment with
miR-1226 inserted as an intron at the site
(50-atcgacttcaagjgaggacggcaaca-30). This was subsequently
sub-cloned back into the pEGFP-Mirt-877 backbone.
Mirtrons under the control of the human Synapsin
promoter were created by removing mirtron containing
eGFP inserts from the pMirt vector using NheI and
HindIII restriction enzymes and sub-cloning them into
the AAV-6P-SEWB backbone (a kind gift from Dr
Sebastian Ku¨gler, Goettingen, Germany) (18) using com-
plementary restriction site overhangs. Pre-miRNA expres-
sion plasmids were designed with mirtron stem–loops
being transcribed off a U6 promoter. PCR was performed
with Pol-III U6 promoter as template and pre-miRNA as
30-primer as previously reported (14). PCR products were
TA-cloned into the pGEM-T Easy vector (Promega) to
generate pol-III expressed pre-miRNA plasmids. Target
sequences of mirtrons used in the luciferase assay were
synthesized as annealed complementary primers and
ligated into psiCheck2.2 vector (Promega, USA) with
XhoI and NotI restriction sites.
Cell culture, transfections and luciferase assays
HEK-293 cells (ATCC, CRL-1573) and SH-SY5Y cells
(ATCC, CRL-2266) were cultured in DMEM supple-
mented with 10% fetal calf serum. For transfection, cells
were grown in 24-well plates to 80% conﬂuence before
mirtrons/pre-miRNAs and target plasmid constructs
were each transfected at a concentration of 500 ng/ml in
HEK-293 cells with Lipofectamine 2000 (Invitrogen,
USA). Luciferase activity was assessed using dual-
luciferase reporter assay system (Promega, USA) and
Wallac-Victor 2 plate reader as per manufacturer’s in-
structions at 48 h post-transfection. Ratios of renilla
luciferase:ﬁreﬂy luciferase were obtained and normalized
to speciﬁc construct controls utilizing the same promoter.
Transfection of NAD and mirt-LRRK2-5NB into
SH-SY5Y cells was carried out at 500 ng/ml followed by
culture in media containing G418 (Sigma Aldrich, USA)
selection antibiotic at a concentration of 50 mg/ml for 3
weeks. Subsequently, cells were maintained in media con-
taining G418 at 10 mg/ml until experiments.
GFP quantiﬁcation
peGFP-Mirt-transfected HEK-293 cells were lysed at
indicated time points and protein content determined
using the micro BCA protein assay (Pierce
Biotechnology, USA). Fifty micrograms of protein was
assayed for GFP ﬂuorescence using a Wallac–Victor
plate reader before subtracting background ﬂuorescence
determined from cells transfected with target alone.
RT–PCR and RT–qPCR
HEK-293 cells were lysed at 48 h post-transfection and
RNA harvested using the Trizol protocol (Invitrogen).
One milligram of total RNA was reverse transcribed
with random hexamers using the Precision Reverse
Transcription kit (PrimerDesign, UK) as per the manufac-
turer’s instructions. Real-time TaqMan PCR was per-
formed with 25 ng of cDNA using TaqMan universal
PCR master mix (Applied Biosystems, USA) and
TaqMan Gene Expression Assay probes (LRRK2:
Hs00417273_m1, Beta-actin: TaqMan beta-actin detection
reagents 401 846 Dual Applied Biosystems) as per the
manufacturer’s instruction.
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Argonaute RNA immuno-precipitation and RT–PCR
analysis
AGO1-4 RIP was carried out with modiﬁed protocol from
Galgano et al. (19). HEK-293 cells were transfected with
1 mg intron variant (NAD, mirt-miR-LRRK2-5NB)
together with stated FLAG-tagged AGO protein (20)
(Addgene plasmids 19 887-19890) or mock plasmid. At
48 h post-transfection, cells were washed two times with
PBS, trypsinized and pelleted. Cells were re-suspended in
500 ml of lysis buffer (50mM Tris–HCL, 10mM NaCl,
0.5% Igepal CA-630, 1mM ethylenediaminetetraacetic
acid (EDTA)) before protein concentration was
determined with the Bio-Rad Protein assay (Bio-Rad,
CA, USA). Subsequently, 200 mg of samples was aliquoted
out for further experiments and made up to 500 ml with
lysis buffer. Further analysis had subsequently been
normalized to sample protein content. AGO proteins
were immuno-precipitated for 1 h with 1 mg M2 anti-Flag
antibody (Sigma Aldrich, USA) that had been
pre-incubated with 30 ml of Dynal protein G magnetic
beads (Invitrogen, USA). Beads were separated, and the
lysate retained for total RNA extraction using the Trizol
extraction method before re-suspension in 30 ml water.
Beads were washed three times in wash buffer 1 (50mM
Tris–HCL, 150mM NaCl, 1mM MgCl2 0.05% Igepal
CA-630) before being re-suspended in 50 ml of sodium
dodecyl sulphate (SDS)–EDTA elution buffer (50mM
Tris, pH 8, 100mM NaCl, 10mM EDTA, 1% SDS) and
heated to 70C for 10min. Beads were separated and
frozen while elute was retained. A total of 20 ml of one
replicate of elute was used for analysis of
immuno-precipitation with western blotting, while re-
maining replicates underwent Trizol extraction of total
RNA before re-suspension in 15 ml water.
For small RNA detection, 2 ml of elute or total RNA
was used for small RNA stem-loop reverse transcriptase
(RT)–PCR using Applied Biosystems TaqMan reverse
primers and TaqMan probes against miR-16, mirt-miR-
LRRK2-5NB and RNU-24 (Applied Biosystems). Stem–
loop reverse transcription of miRNAs was performed with
superscript III reverse transcriptase according to the
manufacturer’s instructions and as previously described
(21). For radioactive PCR and visualization of products,
1.33 ml of cDNA was used in 20 ml reactions with PCR
Master Mix (Applied Biosystems) supplemented with
32P-dCTP. Following qPCR analysis to ensure products
were in the linear range, 34 cycles were performed for
miR-16, 34 cycles for RNU-24 and 39 cycles for
mirt-miR-LRRK2-5NB. Samples were run on a 6%
TBE-gel, immobilized using GelBond PAG ﬁlm (Lonza,
Switzerland) and autoradiography exposure was
carried out.
High throughput sequencing
HEK cells grown in 24-well plates were transfected with
500 ng of stated mirtron. Small RNA libraries were
prepared with the Small RNA v1.5 Sample Prep Kit fol-
lowing the manufacturer’s instructions (Illumina).
Libraries were sequenced on a Genome Analyzer IIx for
36 cycles following the manufacturer’s protocols. The
image analysis and base calling were done using
Illumina’s GA Pipeline. Adapters were trimmed with
Biopieces remove_adapter script, and remaining sequences
were aligned against full-length mirtron hairpins.
Statistical analysis
Statistical signiﬁcance between control and experimental
values was determined using Student’s t-test (paired, two-
tailed). All data are expressed as means ± standard devi-
ation unless otherwise stated.
RESULTS
Mmu-miR-1224 is a splicing-dependent mammalian
mirtron
Success in RNAi effector design has previously beneﬁted
from incorporating antisense sequences targeting genes of
interest into endogenous miRNA sequences (7,22). This
retains evolutionarily selected recognition sequences for
efﬁcient processing of RNAi effectors by RNAi pathway
elements such that they maximize likelihood of correct
processing and successful silencing. Work in our labora-
tory has identiﬁed the mmu-miR-1224 as a potentially at-
tractive mirtron to engineer to target genes of interest (14).
Speciﬁcally, this mirtron has a long poly-pyrimidine tract
in the 30-arm that leads to highly efﬁcient splicing from a
GFP reporter plasmid and a silencing ability comparable
to U6-transcribed pre-miRNA hairpins.
To understand the essential features of this mirtron, the
85-nt long mmu-miR-1224 sequence was placed into a
modiﬁed eGFP expression plasmid, peGFP-Mirt, as an
intron within the eGFP open reading frame (mirt-miR-
1224) such that the splicing ability of the intron could be
readily determined by the presence of eGFP ﬂuorescence
(Figure 1A). Variants of the mirt-miR-1224 mirtron were
generated in which mutations were made to key regulatory
sequences required for splicing (Figure 1A). Construct
mirt-miR-1224DUS (double un-spliceable) included
changes to both the 50-GU and 30-AG splice site recogni-
tion sequences located at the 50- and 30-termini of
mmu-miR-1224, which are considered essential for
splicing (Figure 1A). Constructs mirt-miR-1224BP1-8
(branch point) incorporated mutations to adenosine nu-
cleotides located at sequential positions around the
miR-1224 hairpin loop that could represent the site of
20–50 diester linkage at the branch point (Figure 1A).
This linkage is considered essential for the formation of
intermediate branched lariat precursors of the splicing
reaction (23). A ﬁnal construct, mirt-miR-1224NB (no
bridge), was generated in which an unpaired row of 6 nt
in the 30-arm of mmu-miR-1224 was excluded in order to
see how removal of this secondary structure bulge affected
processing and silencing (Figure 1A).
Following transfection of mirt-miR-1224 into HEK-293
cells, strong eGFP ﬂuorescence was seen that was qualita-
tively and quantitatively comparable to that of a 91-nt
control NADH-coenzyme Q reductase intron 6 (NAD
intron) that lacks hairpin-forming potential (Figure 1B
and C). This successful splicing and restoration of a func-
tional eGFP mRNA transcript was abrogated by
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mutations made to the 50- and 30-consensus splice sites of
mirt-miR-1224DUS as would be expected if mmu-miR-
1224 was a functional intron. Interestingly, while most of
the mirt-miR-1224BP variants displayed non-signiﬁcant
effects on eGFP production relative to the wild-type
mirt-miR-1224 variant, two of these mutants, mirt-miR-
1224BP1 and mirt-miR-1224BP2, almost completely
eliminated eGFP production suggesting that these two
nucleotides may be located in the predominant branch-
point location (Figure 1B and C). These two adenines are
within close proximity to one another suggesting they both
contribute to the branch-point recognition sequence,
although it is unclear which of the two is the site of
20-phospho-diester linkage in the branched lariat.
Collectively the data of these mirt-miR-1224BP variants
suggest that maintenance of the miR-1224 loop is likely
essential for efﬁcient splicing of this intronic sequence
and for the designs of artiﬁcial miR-1224 mimics. Finally,
expression of mirt-miR-1224NB still resulted in eGFP ex-
pression that was quantiﬁed as being 60% relative to that of
the control NAD intron, compared to 69% for mirt-1224
(Figure 1B and C). This difference was not statistically sig-
niﬁcant and suggests that removal of the secondary struc-
ture bulge that forms part of the poly-pyrimidine tract of
miR-1224 may have little, if any, contribution to improving






Figure 1. miR-1224 is splicing-dependent mammalian mirtron processed into small RNA species capable of directing RNAi. (A) Predicted hairpin
alignment of murine miR-1224 with boxes indicating variant sequences modiﬁed in stated constructs. (B) Representative ﬂuorescent microscopy
images of different mirt-miR-1224 variants at 48 h after transfection in HEK-293 cells. (C) Quantiﬁcation of eGFP ﬂuorescence following 48 h
expression of stated miR-1224 variants in HEK-293. Values represent mean ﬂuorescence ±SD from n=3. *P< 0.05 relative to non-transfected cells.
Additionally displayed are P values for differences relative to the mirt-miR-1224 variant. (D) Dual-luciferase reporter assays showing knockdown of
a miR-1224 target following co-transfection with indicated mirtron (blue bars) or pre-miRNA (red bars) variants. Values represent mean ratios of
Renilla:Fireﬂy luciferase±SD from n=6. Mirtron variants are normalized to cells transfected with the NAD variant. Pre-miRNA variants are
normalised to cells transfected with a non-speciﬁc U6 pre-miRNA hairpin. *P< 0.05 relative to respective normalizing control. (E) Small RNA
sequencing from mirt-miR-1224-transfected HEK-293 cells.
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The miRNA derived from the 50-arm of miR-1224 is
enriched in cloning libraries of small RNAs compared to
that derived from the 30-arm indicating that it harbours
the mature miRNA species (15). To test RNAi silencing of
mirt-1224 variants, a dual-luciferase vector was created
that carried a target sequence fully complementary to
the miR-1224 50 sequence in the 30-untranslated region
(UTR) of Renilla luciferase gene. Relative to the NAD
intron, mirt-miR-1224 silenced this target by 83%
(P< 0.001) (Figure 1D). This silencing was completely
abolished by construct mirt-miR-1224DUS to suggest
mirt-miR-1224 directed silencing in a splicing-dependent
manner (Figure 1D). Despite reduced eGFP ﬂuorescence
levels when using construct mirt-miR-1224NB, silencing
levels achieved by this construct were directly equivalent
to mirt-miR-1224 at 83% (P< 0.001), a result that is con-
sistent with efﬁcient hairpin formation via RNAi
processing.
To eliminate the possibility that the mutations
introduced into this splicing-deﬁcient variant directly
affected knockdown of the target, U6-driven
pre-miRNA controls were generated that corresponded
to putatively spliced mirtron variants in order to isolate
sequence-dependent effects. Expression of the pre-miR-
1224DUS variant alongside the miR-1224 luciferase
target sequence led to an equivalent silencing of 87%
(P< 0.001) compared to the respective wild-type
pre-miR-1224 variant, which silenced by 85%
(P< 0.001) (Figure 1D). This conﬁrmed that the
introduced mutations abrogated silencing of mirtron
variants by inhibiting splicing rather than through direct
effects on target recognition and RNAi silencing. Despite
the slightly reduced splicing efﬁciency of mirt-1224NB, the
pre-miRNA variant of this construct, pre-miR-1224NB,
was also able to direct a comparable silencing (81%;
P< 0.001) relative to the pre-miR-1224 variant (Figure
1D). These data support a model where a strong second-
ary structure of the predicted hairpin of mirt-1224NB
leads to efﬁcient recognition and/or processing of this
modiﬁed hairpin by RNAi pathway elements following
intron splicing. These effects may compensate for
mirt-miR-1224NB’s slightly reduced splicing activity.
Finally, to conﬁrm that an RNAi mechanism was
indeed responsible for the silencing effect, small RNA
species were deep-sequenced from mirt-miR-1224-trans-
fected HEK-293 cells. Within the 1 766 495 reads that
mapped to human miRNAs from four pooled samples, a
relatively small total of 32 reads mapped to the hairpin
region of the mirt-1224 construct, all of which derived
from the 50-arm from which the predicted mature species
derives (Figure 1E). No reads were detected from other
regions of the mirt-1224 hairpin. This small number agrees
with our previous ﬁndings that mirtrons produce guide
strands in low abundance despite their relatively potent
silencing efﬁcacy when compared to other RNAi effectors
(14). Moreover, the 50-ends of all reads map to the 50-nu-
cleotide of the intron, thus ensuring accurate guide strand
production and minimal exonuclease trimming following
mirtron splicing. Taken together, the results suggest
miR-1224 intron is both spliced and processed into small
RNA species that can direct silencing of a complementary
target sequence through an RNAi-like mechanism in a
manner that is splicing dependent. The results conﬁrm
the classiﬁcation of miR-1224 as a mammalian mirtron
(15) and expand on previous understanding of the
sequence constraints of this mirtron (14).
Design of artiﬁcial mirtrons targeting the LRRK2
sequence
In order to design artiﬁcial mirtrons targeting genes of
interest, sequences in the PD-associated LRRK2 mRNA
sequence were searched for target sequences amenable to
both splicing and RNAi requirements for efﬁcient mirtron
biogenesis. LRRK2 was selected given that genetic
ablation of LRRK2 is protective in PD transgenic mice
carrying a-synuclein mutations, suggesting that silencing
of LRRK2 could be therapeutically beneﬁcial in PD (24).
Speciﬁcally, we screened the LRRK2 open reading frame
(ORF) for pyrimidine-rich regions, which were comple-
mentary to the human consensus splice-site sequence of
GURRR, where R is an A or G (25). This rule was
applied so that the corresponding antisense species could
in theory be inserted into the 50-arm of the miR-1224
backbone. The list of candidates were then
cross-compared to candidate lists deﬁned by publically
available RNAi design algorithms in order to rank poten-
tial target sequences based on their ability to fulﬁl both
splicing and RNAi requirements. Where possible, comple-
mentary sequences to the highest rated target sequences in
the RNAi algorithms were subsequently incorporated into
the miR-1224 hairpin and inserted into the eGFP ORF.
Of the top 10 hits against LRRK2, 4 were chosen to be
incorporated into the miR-1224 backbone based on fa-
vourable alignments (Figure 2A). A ﬁfth construct was
additionally designed based on what was considered to
be the most favourable alignment of construct
mirt-LRRK2-5. In this construct, named mirt-LRRK2-
5-No-Bridge (mirt-LRRK2-5NB), the 6-nt sequence that
forms a bulge within the sense arm directly opposite the 30-
end of the antisense species of miR-1224 was removed.
This was in order to investigate whether the stronger sec-
ondary structure of the hairpin would affect processing in
a way similar to that shown previously for
mirt-miR-1224NB.
Transfection into HEK-293 cells revealed that all arti-
ﬁcial LRRK2 mirtrons were spliced to levels qualita-
tively comparable to the previously validated mirt-1224
construct and control NAD intron (Figure 2B).
Quantiﬁcation of ﬂuorescence revealed that mirt-
LRRK2-5 and mirt-LRRK2-8 were impressively 91%
and 88% as efﬁcient as the NAD intron, respectively,
while the removal of the 30-sequence in mirt-LRRK2-
5NB acted to decrease the splicing ability of this construct
relative to mirt-LRRK2-5, potentially as a result of a
shorter poly-pyrimidine tract (Figure 2C, P< 0.001). It
therefore appears that the importance of this bulge is
context-dependent, and in the case of this artiﬁcial
mirtron the bulge contributes to the splicing efﬁciency of
the short intron. Co-transfection with a dual-luciferase
reporter plasmid bearing a single large target sequence
to all ﬁve LRRK2 mirtrons revealed that four out of
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ﬁve variants were able to silence the target. While
mirt-LRRK2-2 and mirt-LRRK2-8 silenced the target
by 20%, both mirt-LRRK2-5 and mirt-LRRK2-5NB
were capable of directing 68% (P< 0.001) and 85%
(P< 0.001) silencing, respectively (Figure 2D). Thus,
while the removal of the 30-bulge acted to reduce
splicing efﬁciency, it had the desirable beneﬁt of increasing
the knockdown efﬁciency of the mirt-LRRK2-5NB
variant (P< 0.001). This could be the result of a thermo-
dynamically more stable hairpin being produced, which is
processed more efﬁciently by the RNA-induced silencing
complex. Supporting this hypothesis is the lower G value
for the predicted secondary structure of
mirt-LRRK2-5NB using the mFold secondary structure
prediction algorithm (26): mirt-LRRK2-5=7.88 kcal
mole1 and mirt-LRRK2-5NB=13.76 kcal mole1.
However, comparison of silencing by U6-transcribed
pre-miR-LRRK2-5NB and pre-miR-LRRK2-5 revealed
near identical levels of silencing of 83% (Supplementary
Figure S1). This may be because the high rate of
U6-driven transcription of these hairpins masks subtle
differences seen when the mature species are produced at
lower levels as is the case with the mirtron variants.
Irrespective of the reason for this difference, the results
suggest that both variants are likely functional artiﬁcial
mirtrons capable of silencing LRRK2 target sequences.
We next decided to further investigate the putative
mirtron origins and capabilities of mirt-LRRK2-5NB
due to its impressive silencing ability. To test whether
LRRK2-5NB was indeed a functional intron, a U!C
mutation was made to the 50-splice site in construct
mirt-LRRK2-5NBUS (Figure 3A). Pre-miRNA variants
of both LRRK2-5NB (pre-miR-LRRK2-5NB) and
LRRK2-5NBUS (pre-miR-LRRK2-5NBUS) were also
generated to determine if the mutations made to
mirt-LRRK2-5NBUS directly affect the silencing of this
construct. As predicted, mutations made to mirt-LRRK2-
5NBUS now resulted in no eGFP ﬂuorescence when ex-
pressed for 48 h in HEK-293 cells (Figure 3B). Silencing of
the LRRK2 target by mirt-LRRK2-5NBUS was also
reduced to non-signiﬁcant levels, suggesting that mirt-




Figure 2. Design of artiﬁcial mirtrons targeting LRRK2. (A) Predicted hairpin alignments of LRRK2 targeting artiﬁcial mirtrons. (B) Representative
ﬂuorescent microscopy images of different artiﬁcial mirtron variants targeting LRRK2 48 h after transfection in HEK-293 cells. (C) Quantiﬁcation of
eGFP ﬂuorescence following expression artiﬁcial mirtron variants targeting LRRK2 in HEK-293 cells. Values represent mean ﬂuorescence±SD
from n=3. *P< 0.05 relative to non-transfected cells. (D) Dual-luciferase reporter assays showing knockdown of a LRRK2 target following
co-transfection with indicated mirtron variants. Values represent mean ratios of Renilla:Fireﬂy luciferase±SD from n=6. *P< 0.05 relative to
respective normalizing control.
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manner (Figure 3C). Indeed, both pre-miR-LRRK2-5NB
and pre-miR-LRRK2-5NBUS were capable of silencing
the target by 84% (P< 0.001) and 80% (P< 0.001),
respectively. This means that mutations made to the
unspliceable construct do not directly affect the ability
of the antisense sequence to direct silencing and in-
stead mediate their effect through abrogation of splicing
(Figure 3C).
Next, a codon-modiﬁed, scrambled target to
mirt-LRRK2-5NB was generated in order to test the
sequence speciﬁcity of the interaction between LRRK2-
5NB and its target sequence (Supplementary Figure S2).
Speciﬁcally, the third nucleotide of each codon in the
target site was changed to an alternate nucleotide such
that the scrambled sequence would still be transcribed
into the same amino-acid sequence due to redundancy in
the triplet code. As expected, both pre-miRNA variants
and mirt-LRRK2-5NB showed a decreased ability to
silence the scrambled target implying that silencing is a
sequence-speciﬁc effect that strongly resembles an
RNAi-like mechanism (Supplementary Figure S2). This
was further conﬁrmed by the detection of small RNA
species corresponding predominantly to the 50-arm of
mirt-LRRK2-5NB following deep sequencing of trans-
fected HEK-293 cells (Figure 3D). As with miR-1224, a
relatively modest 55 reads out of the 1 766 495 small RNA
reads from four pooled samples mapped to mirt-miR-
LRRK2-5NB. Importantly, using RNA immuno-
precipitation of FLAG-tagged Argonaute (AGO)






Figure 3. mirt-LRRK2-5NB is a splicing-dependent artiﬁcial mirtron. (A) Predicted hairpin alignments for mirt-LRRK2-5NB sequences to be
incorporated into the pMirt vector. Variant with modiﬁcations made to splicing regulatory sequences is indicated by dashed boxes.
US=unspliceable. (B) Representative ﬂuorescent microscopy images of different mirt-LRRK2-5NB variants 48 h after transfection in HEK-293
cells. (C) Dual-luciferase reporter assays showing knockdown of a LRRK2 target following co-transfection with indicated mirtron (left panel) and
pre-miRNA control (right panel) variants. Values represent mean ratios of Renilla:Fireﬂy luciferase+SD from n=6. Mirtron variants are
normalized to cells transfected with the NAD variant. Pre-miRNA variants are normalised to cells transfected with a non-speciﬁc U6
pre-miRNA hairpin. *P< 0.05 relative to respective normalizing control. (D) Small RNA sequencing from mirt-LRRK2-5NB-transfected
HEK-293 cells. (E) Radio-labelled RT–PCR of miR-16 (34 cycles), mirt-miR-LRRK2-5NB (39 cycles) and RNU-24 (34 cycles) from total RNA
or FLAG immuno-precipitated elutes of cells transfected with mirt-miR-LRRK2-5NB together with FLAG-tagged AGO proteins or a non-FLAG
mock transfection. (F) RT–PCR of SH-SY5Y cell total RNA using primers speciﬁc for LRRK2. Expected size 191 bp. (G) Representative ﬂuorescent
images of SH-SY5Y cells transfected with either the NAD intron or mirt-LRRK2-5NB and maintained in G418 selection marker for four weeks.
(H) Relative expression of the LRRK2 transcript determined with RT–qPCR following transfection of SH-SY5Y cells with the NAD intron or
mirt-LRRK2-5NB. Values represent mean expression relative to b-actin expression±SD and n=6. Transcript levels in the presence of
mirt-LRRK2-5NB are normalized to cells transfected with NAD intron.
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were enriched in FLAG-tagged AGO1-4 elutes relative to
mock-transfected cells in a similar way to the canonical
miRNA, miR-16, but not the small nucleolar RNA,
RNU-24 (Figure 3E). Small RNA detection of miR-16
and mirt-miR-LRRK2-5NB in total RNA fractions is
expected to be due to mature RNA present in endogenous
AGO1-4 proteins that is not immuno-precipitated by the
FLAG antibody. Collectively, these results provide
compelling evidence that artiﬁcial mirtrons function
through the RNAi pathway to silence cognate target
sequences.
We next investigated how artiﬁcial mirtrons compared
to existing RNAi methodologies. To do this, identical
2.5ƒm amounts of the LRRK2-5NB hairpin sequence in
either a U6-transcribed pre-miRNA or mirtron context
were transfected with the dual-luciferase target.
Encouragingly, the silencing by these two constructs at
these equivalent concentrations was near identical (91%
pre-miR-LRRK2-5NB, 87% mirt-miR-LRRK2-5NB,
P< 0.01) when compared to the target alone condition,
suggesting that mirtrons have comparable efﬁcacy to
pre-miRNA/shRNA effectors (Supplementary Figure S3).
As a ﬁnal test of LRRK2-5NBs potential, attempts were
made to detect knockdown of endogenous, full-length
LRRK2 transcripts by this artiﬁcial mirtron. RT–PCR
was initially used to determine that LRRK2 was expressed
in the human dopaminergic SH-SY5Y cell line (Figure 3F).
Subsequently, constructs containing the NAD intron and
mirt-LRRK2-5NB were transfected into SH-SY5Y cells
and cells grown in G418 selection marker to enrich for
transfection for 4 weeks. Analysis of eGFP-ﬂuorescence
from the NAD intron and LRRK2-5NB constructs con-
ﬁrmed that nearly all surviving cells at this time produced
eGFP-ﬂuorescence (Figure 3G). Furthermore, endogenous
LRRK2 transcripts were reduced 36% (P< 0.05) to
conﬁrm that artiﬁcial mirtrons may also effectively direct
silencing of endogenous gene targets (Figure 3H). The
reduction in silencing relative to the dual-luciferase
assays may be due to a less accessible target site within
the secondary structure of the full-length LRRK2 tran-
script. Alternatively, 30-UTR targeting for the dual-
luciferase reporter biases incorporation of guide strands
into AGOs 1–4, whereas only AGO2 can function when
targeting the coding sequence. Arguing against this second
point and favouring the ﬁrst is the fact that we have previ-
ously designed shRNAs against 30-UTR luciferase targets
that work well against full-length open reading frames
(27,28), suggesting that AGO protein availability is not
the limiting factor in the silencing effect. Attempts were
made to transiently transfect U6 hairpins into SH-SY5Y
to test whether the pre-miRNA variants also have limited
silencing of LRRK2. However, the limited transfection
efﬁciency in these cells precluded detection of a silencing
effect.
Targeting of a-synuclein with miR-1224 mimics
To conﬁrm that miR-1224 can be used as a structural
backbone for artiﬁcial mirtron mimics targeting other
genes of interest, we applied the previously described
approach to design artiﬁcial mirtrons to the ORF of
human a-synuclein that is also linked to PD. Like
LRRK2, the silencing of a-synuclein has potential as a
therapy for PD (29). Six artiﬁcial mirtron sequences
were designed and tested against this gene, and a single
variant found to be spliced and silence a corresponding
luciferase and full-length target. Construct a-syn-mirt-1
was shown to splice to levels 26% of the NAD intron,
and silence a fully complementary luciferase target by
26% (P< 0.05) and a full-length mCherry-tagged tran-
script by 27% (P< 0.05, Supplementary Figure S4). This
modest level of silencing could be due to the poor splicing
efﬁciency or alternatively due to an inefﬁcient RNAi
effector being generated following splicing. Despite the
limited eGFP expression, the latter explanation is
favoured since a pre-miRNA control variant of
a-syn-mirt-1 was shown to silence the dual-luciferase
target by a comparable 33% (P< 0.05) to the mirtron
variant (Supplementary Figure S4), indicating that the
mature hairpin produced is not a strong RNAi effector.
Collectively, the results demonstrate that
mirt-LRRK2-5NB is not unique and that artiﬁcial
mirtrons based on miR-1224 can be designed targeting
other genes of interest.
LRRK2-5NB can direct cell type-speciﬁc silencing when
expressed off neuron-speciﬁc pol-II promoters
Having demonstrated that functional artiﬁcial mirtrons
could be designed, we next investigated some of the
putative advantages of such an artiﬁcial mirtron system.
One potential beneﬁt of using artiﬁcial mirtrons is that
silencing could be directed to speciﬁc cell types of
interest. To investigate this, a previously validated
promoter was sourced with properties, making it
suitable for pairing with the LRRK2-5NB mirtron. The
human synapsin-1 (hSYN) minimal promoter has previ-
ously been demonstrated to direct neuronal-speciﬁc ex-
pression of eGFP when incorporated into an
AAV-vector and delivered into the rat brain (18).
To generate hSYN-pMirt constructs, eGFP variants
carrying the NAD intron, LRRK2-5NB or LRRK2-
5NBUS were excised from respective pMirt vectors and
ligated downstream of the hSYN promoter in the
AAV-6P-SEWB expression plasmid (18). Transfection of
the LRRK2-5NB dual-luciferase target together with each
of the hSYN constructs was carried out in the unrelated
HeLa and SH-SY5Y cell lines to test for cell speciﬁcity of
expression and silencing. At the same time, CMV
promoter-driven constructs were transfected under identi-
cal conditions for comparison of ﬂuorescence and
silencing efﬁcacy between the identical constructs under
the control of the different promoters. While levels of
eGFP expression were somewhat smaller than in
HEK-293 cells largely due to transfection efﬁciency, the
use of a CMV promoter successfully resulted in detectable
eGFP expression for the NAD and mirt-LRRK2-5NB
constructs but not the mirt-LRRK2-5NBUS in both
cell-lines, with ratios between the two comparable to
that seen previously in HEK-293 cells (Figure 4A and C;
Supplementary Figure S5). This agrees with the ubiqui-
tous expression patterns expected of the CMV promoter.
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In contrast, hSYN-directed low-level expression of eGFP
from NAD and mirt-LRRK2-5NB constructs in the
neuronal SH-SY5Y but not in HeLa cell line (Figure 4A
and C; Supplementary Figure S5). This conﬁrms a
neuronal-speciﬁc expression pattern of the hSYN
promoter as reported previously.
To determine if gene silencing was also directed in a
cell-type-speciﬁc manner, dual-luciferase assays were per-
formed at 48 h post-transfection. Use of the CMV
promoter resulted in signiﬁcant levels of silencing of the
LRRK2-5NB target by 75% (P< 0.05) and 48%
(P< 0.05) in Hela and SH-SY5Y cells, respectively, with
LRRK2-5NBUS failing to silence the target (Figure 4B
and D). However, expression with the hSYN promoter
resulted in signiﬁcant silencing of the target by
mirt-LRRK2-5NB in SH-SY5Y cells by 29% (P< 0.05),
respectively, but not in HeLa cells (Figure 4B and D).
While improved promoter activity is desirable, collectively
the data imply that silencing by mirtrons can be directed
in a cell-type-speciﬁc manner under the hSYN promoter.
Co-delivery of multiple mirtrons within one host transcript
An additional advantage of using artiﬁcial mirtrons over
several other RNAi strategies is that multiple mirtrons can
in theory be included within a single host transcript to
direct combinatorial RNAi. This can either be used to
enhance silencing of the desired target by including
multiple copies of the same mirtron or different mirtrons
targeting the same transcript, or alternatively it could be
used to silence multiple gene targets by incorporating dif-
ferent mirtrons. As a preliminary step towards developing
this application for future studies, a dual-construct,
pMirt-Dual, was produced which contained both previ-
ously validated mirtrons, mirt-miR-877 and mirt-miR-
1226 (14), as introns within the eGFP transcript separated
by a 90-nt exon (Figure 5A). Fluorescence microscopy and
eGFP ﬂuorescence quantiﬁcation after expression of the
construct in HEK-293 cells showed that splicing to
produce a functional eGFP transcript was evident
(Figure 5B and C). Interestingly, the pMirt-Dual construct
generated ﬂuorescence at 55% of the level of the NAD
intron which is signiﬁcantly greater than the single
mirt-miR-877 construct (P< 0.01) and equivalent to that
of mirt-miR-1226. This suggests that the splicing efﬁciency
of mirt-miR-877 can be improved through incorporation
of a stronger intron. Importantly, co-transfection with
either the miR-877 or miR-1226 targets demonstrated
that the dual-mirtron construct was able to silence both
A B
C D
Figure 4. LRRK2-5NB can be expressed in a cell-type speciﬁc manner using the human synapsin promoter. (A) Representative ﬂuorescent images of
mirt-LRRK2-5NB expressed off the CMV or human synapsin promoter in SH-SY5Y cells. (B) Dual-luciferase reporter assays showing knockdown
of a LRRK2 target following co-transfection with indicated mirtron variants expressed off the CMV (left panel) or human synapsin (right panel)
promoter in SH-SY5Y cells. Values represent mean ratios of Renilla:Fireﬂy luciferase±SD from n=3. Mirtron variants are normalized to cells
transfected with the NAD variant. Pre-miRNA variants are normalised to cells transfected with a non-speciﬁc U6 pre-miRNA hairpin. *P< 0.05
relative to respective normalizing control. (C) Representative ﬂuorescent images of mirt-LRRK2-5NB expressed off the CMV or human synapsin
promoter in Hela cells. (D) Dual-luciferase reporter assays showing knockdown of a LRRK2 target following co-transfection with indicated mirtron
variants expressed off the CMV (left panel) or human synapsin (right panel) promoter in Hela cells. Values represent mean ratios of Renilla:Fireﬂy
luciferase±SD from n=3. Mirtron variants are normalized to cells transfected with the NAD variant. Pre-miRNA variants are normalized to cells
transfected with a non-speciﬁc U6 pre-miRNA hairpin. *P< 0.05 relative to respective normalizing control.
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reporter constructs to near identical levels to each of the
respective single mirtron constructs, while the single mirt-
miR-877 or mirt-miR-1226 constructs were only able to
silence their own respective gene targets (Figure 5D). The
results conﬁrm that multiple mirtrons can be incorporated
into a single host gene to effectively silence target tran-
scripts and suggests that mirtrons could be used for future
combinatorial RNAi applications.
DISCUSSION
In this report, we show that artiﬁcial mirtrons represent a
new type of expressed RNAi trigger to be added to the
ever-growing arsenal of RNAi effectors. Speciﬁcally, we
have identiﬁed key sequence elements required for splicing
in the miR-1224 mirtron. These have then been incorpor-
ated into artiﬁcial miR-1224 mimics placed within the
eGFP ORF, which successfully direct silencing of the
human LRRK2 and a-synuclein target sequences in a
splicing and RNAi-dependent manner. Finally, we have
demonstrated advantages of using artiﬁcial mirtron
mimics such as pol-II-regulated silencing and combinator-
ial delivery of multiple mirtron effectors. This work opens
the use of artiﬁcial mirtrons as a new method for targeted
silencing of genes-of-interest in which advantages of the
mirtron system can be exploited for therapeutic beneﬁt.
The design of artiﬁcial mirtrons is a challenging task




Figure 5. Combinatorial delivery of multiple artiﬁcial mirtrons in a single host transcript. (A) Schematic of pMirt-dual which carries both the
mirt-miR-877 and mirt-miR-1226 mirtrons. (B) Representative ﬂuorescent images of HEK-293 cells expressing indicated mirtron variants at 48 h
post-transfection. (C) Quantiﬁcation of eGFP ﬂuorescence following expression indicated intron variants in HEK-293 cells. Values represent mean
ﬂuorescence±SD from n=3. *P< 0.05 relative to non-transfected cells. (D) Dual-luciferase reporter assays showing knockdown of a target
complementary to the 50-arm of mirt-miR-877 (left panel) or the 30-arm of mirt-miR-1226 (right panel) following co-transfection with indicated
mirtron variants in HEK-293 cells. Values represent mean ratios of Renilla:Fireﬂy luciferase±SD from n=3. Mirtron variants are normalized to
cells transfected with the NAD variant. *P< 0.05 relative to respective normalizing control.
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met in order for success. Here, screening ORFs for
pyrimidine-rich regions with complementarity to a theor-
etical purine-rich 50 splice site based on the human con-
sensus sequence of GURRR [where R is an A or G (25)]
was used to narrow down potential candidate target sites
of artiﬁcial miR-1224 mimics, which would use the 50-arm
as the mature species. Candidates were then compared
against results of the same ORFs ﬁltered through RNAi
design algorithms to identify the highest scoring RNAi
effectors that match the desired splicing requirements.
Using this simple approach, we were able to design artiﬁ-
cial mirtrons that successfully silenced the LRRK2 and
a-synuclein sequences.
An impressive 85% silencing was achieved by one arti-
ﬁcial mirtron, mirt-LRRK2-5NB, against a
dual-luciferase LRRK2 target sequence that was directly
comparable to the silencing by a U6-transcribed
pre-miRNA hairpin (shRNA) targeting the same
sequence. This is promising since it suggests that artiﬁcial
mirtrons can silence on a par with one of the most
commonly used RNAi approaches, and to levels desirable
to RNAi researchers. However, this level of silencing was
not seen when targeting the full-length LRRK2 endogen-
ous transcript where 36% knockdown was demonstrated.
Despite this, the difference should not detract from the
proof-of-principle of using artiﬁcial mirtrons since the
reduced silencing of the endogenous target can be ex-
plained by features speciﬁc to this transcript. This most
likely involves a secondary structure of the endogenous
LRRK2 transcript that reduces accessibility to the target
site relative to the 30-UTR of the Renilla luciferase gene.
Indeed, no reduction in silencing was seen between
dual-luciferase targeting and full-length targeting of
a-synuclein by a-syn-mirt-1, despite the modest levels of
silencing achieved, while artiﬁcial mirtrons currently in
early stages of development in our lab have demonstrated
>75% knockdown against full-length targets (data not
shown).
A range of novel strategies for producing RNA-
mediated silencing, such as small internally segmented
interfering RNAs (3), asymmetric interfering RNAs (4),
pri-miRNA mimics (9,28) and pri-miRNA cluster
mimics (7), have been developed in recent years that
address many of the issues associated with employing
RNAi. This includes toxicity due to competition with
the endogenous pathway, toxicity due to off-target
effects, delivery speciﬁcity and prolonged duration of
silencing (8). Current trends in expressed RNAi triggers,
with which artiﬁcial mirtrons should be directly
compared, suggest that pri-miRNA mimics are the most
suitable DNA-encoded approach for therapeutic gene
silencing (9,28). Alternatives of shRNAs and tandem
shRNAs rely on use of ubiquitous pol-III promoters to
drive expression and are therefore difﬁcult to spatially
restrict to cell types of interest using viral tropism alone.
This lack of promoter-regulated speciﬁcity is a major limi-
tation of pol-III transcribed approaches for therapeutic
application and indeed of siRNAs (30,31). Furthermore,
high levels of expression also lead to toxicity in various
pre-clinical models due to competition with the endogen-
ous pathway (9,10). In contrast, pri-miRNA mimics can
be expressed off pol-II promoters that have potential to
direct cell-type-speciﬁc silencing and drive expression at
much lower levels (9,11). Both characteristics can reduce
the off-target effects in heterogeneous populations of cells,
the ﬁrst by restricting exogenous antisense production to
only the cell populations desired, and the second by
providing less competition for the endogenous RNAi
pathway that can be saturated (10).
It is demonstrated here that artiﬁcial mirtrons and
pri-miRNA mimics share the ability to be expressed in a
cell-type-speciﬁc manner using pol-II transcription. We
have shown that the mirt-LRRK2-5NB mirtron could be
driven by the human synapsin promoter to direct silencing
in the neuronal SH-SY5Y cell line but not the cervical
cancer-derived HeLa cell line. Silencing in SH-SY5Y
cells was reduced from 48%% to 29% when using the
human synapsin promoter rather than the CMV
promoter, and it is expected that this is because either
the 495-bp synapsin promoter that was used (18) was a
minimal promoter variant with incomplete activity or al-
ternatively that the synapsin promoter is not strongly
activated in this cell line. Irrespective, this desirable
quality of cell-type-speciﬁc silencing is possible since arti-
ﬁcial mirtrons can be expressed within host mRNA tran-
scripts that have elaborate initiation and termination
signals bearing recognition sequences for cell-type-speciﬁc
transcription factors. As such, the potential for off-target
effects of artiﬁcial mirtrons within heterogeneous popula-
tions of cells is likely to be restricted both by limiting
aberrant expression and expression levels, although this
last point remains to be fully determined experimentally.
Importantly, despite few having been exploited for RNAi
at present, numerous cell-type-speciﬁc promoters have
been identiﬁed, which can now be placed at the disposal
of artiﬁcial mirtrons and pri-miRNA mimics (32,33).
Another promising RNAi approach being investigated
for several therapeutic settings is the combination of gene
silencing with other therapies. This may include delivery
of multiple RNAi effectors when it is beneﬁcial to target
biological pathways rather than single targets in cancers
or complex genetic diseases, or where high rates of viral
mutation dictate that silencing multiple targets is required
to avoid viral tolerance of silencing (34–36). Alternatively,
effectors have been delivered in combination with other
beneﬁcial therapeutics such as genetically corrected target
genes as a means of non-allele speciﬁc correction of
disease-linked mutations (37,38). Delivery of multiple
RNAi effectors and supplementary transgenes has been
hampered by the difﬁculty of co-delivery of the multiple
constructs with their respective promoters in a single
vector. RNAi approaches have been devised, which can
release multiple antisense species from a single transcript
to limit this problem such as tandem shRNAs and
pri-miRNA cluster mimics (6,7). Yet tandem shRNAs
would be expected to suffer the same disadvantages as
pol-III transcribed shRNA constructs, while the potency
of an antisense species is lost the further it is placed away
from the base of the hairpin stem to limit the number of
effectors that can be delivered in one construct (39,40).
Given the advantages of pri-miRNA mimics, the
pri-miRNA cluster mimics are considered the optimal
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combinatorial RNAi delivery mechanism, although these
have been scarcely investigated at present (7).
Here we show that artiﬁcial mirtrons can now be
included alongside the existing approaches being used in
combination therapies since two previously validated
mirtrons, miR-1226 and miR-877 (14), were successfully
delivered within one host construct without any loss of
silencing ability in this study. The incorporation of artiﬁ-
cial mirtrons into the ORF of eGFP also suggests that it
will also be possible for mirtrons to be inserted into alter-
nate ORFs of therapeutically beneﬁcial transgenes to
allow combinatorial therapies driven by a single
promoter. Importantly, the short length of artiﬁcial
mirtrons will not add signiﬁcantly to the packaging size
of the delivery of the host transcript even when multiple
mirtrons are incorporated, making it a useful combinator-
ial approach where restrictions on packaging size are
present such as when using certain viral approaches.
Finally, the small RNA sequencing reads of mirt-miR-
1224 and the mirt-LRRK2-5NB artiﬁcial mirtron import-
antly show that the 50-terminal nucleotide of the mature
species generated is highly reproducible and corresponds
to the ﬁrst nucleotide of these short introns within eGFP.
This was expected since the splicing machinery is initiated
and directed by the presence of essential sequence require-
ments within introns (25,41,42). Recognition allows
splicing to be carried out reproducibly at the same pos-
itions of a pre-mRNA transcript such that identical
spliced introns are produced in each reaction. When con-
sidered in the mirtron pathway, in which the 50- and 30-
ends of the removed intron deﬁne the termini of the
pre-miRNA like substrate, it implies that accurate
pre-miRNA species generation and seed-sequence deﬁn-
ition will occur when the 50-arm represents the mature
strand. Indeed these results were reﬂected in the deep
sequencing reads we obtained for both the natural
mirtron, miR-1224, and our artiﬁcial mirtron,
mirt-LRRK2-5NB. This is important since even shifts of
just 1 nt of the position of the seed region can either lead
to abrogated activity or aberrant off-target effects as new
gene pools are targeted (43). Non-homogenous popula-
tions of both mature and pre-miRNAs have been seen
following pri-miRNA processing implying that Drosha
ﬁdelity is not 100% reproducible (43). Together it
suggests that this may be limiting in therapeutic
approaches utilizing pri-miRNA mimics since the poten-
tial for abrogated activity or increased off-target effects
would be enhanced. Collectively this point could be used
to argue that artiﬁcial mirtrons should be preferable to
pri-miRNA mimics for targeting genes of interest,
although further supporting evidence needs to be collected
before this can be concluded.
In summary, the characteristics of the mammalian
mirtron pathway make the artiﬁcial mirtrons developed
in this study a highly desirable RNAi effector to be
added alongside existing RNAi technologies. Speciﬁcally,
we have shown that artiﬁcial mirtrons can be designed
that direct comparable levels of silencing to existing
RNAi technologies such as U6-driven pre-miRNAs/
shRNAs, silencing can be restricted in a cell-type-speciﬁc
manner and that combinatorial delivery of multiple
mirtrons in one host construct is possible. If the design
of artiﬁcial mirtrons can be optimized further in future,
then their advantages could make them one of the leading
synthetic RNAi effectors available to researchers.
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Supplementary Figures 1–5.
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